In fact, the accumulation of uremic toxins during CKD favors the progression of bone disease across two pathways: skeletal resistance to PTH through the down regulation of the PTH1R receptor expressed by osteoblasts (mediated by indoxyl sulfate) and osteoblast dysfunction (mediated by p-cresyl sulfate or pCS) [41]. This evidence concerns the gene PTH and chronic kidney disease.